Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name><affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name><affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name><affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name><affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name><affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name><affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name><affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></nlm:aff></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26387144</idno><idno type="pmc">4658543</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658543</idno><idno type="RBID">PMC:4658543</idno><idno type="doi">10.1093/annonc/mdv391</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000169</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</title><author><name sortKey="Munzone, E" sort="Munzone, E" uniqKey="Munzone E" first="E." last="Munzone">E. Munzone</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, A" sort="Giobbie Hurder, A" uniqKey="Giobbie Hurder A" first="A." last="Giobbie-Hurder">A. Giobbie-Hurder</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Gusterson, B A" sort="Gusterson, B A" uniqKey="Gusterson B" first="B. A." last="Gusterson">B. A. Gusterson</name><affiliation><nlm:aff id="mdv391_af3"><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mallon, E" sort="Mallon, E" uniqKey="Mallon E" first="E." last="Mallon">E. Mallon</name><affiliation><nlm:aff id="mdv391_af4"><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Viale, G" sort="Viale, G" uniqKey="Viale G" first="G." last="Viale">G. Viale</name><affiliation><nlm:aff id="mdv391_af5"><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Thurlimann, B" sort="Thurlimann, B" uniqKey="Thurlimann B" first="B." last="Thürlimann">B. Thürlimann</name><affiliation><nlm:aff id="mdv391_af6"><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af7"><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Ejlertsen, B" sort="Ejlertsen, B" uniqKey="Ejlertsen B" first="B." last="Ejlertsen">B. Ejlertsen</name><affiliation><nlm:aff id="mdv391_af8"><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Macgrogan, G" sort="Macgrogan, G" uniqKey="Macgrogan G" first="G." last="Macgrogan">G. Macgrogan</name><affiliation><nlm:aff id="mdv391_af9"><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bibeau, F" sort="Bibeau, F" uniqKey="Bibeau F" first="F." last="Bibeau">F. Bibeau</name><affiliation><nlm:aff id="mdv391_af10"><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Lelkaitis, G" sort="Lelkaitis, G" uniqKey="Lelkaitis G" first="G." last="Lelkaitis">G. Lelkaitis</name><affiliation><nlm:aff id="mdv391_af11"><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></nlm:aff></affiliation></author><author><name sortKey="Price, K N" sort="Price, K N" uniqKey="Price K" first="K. N." last="Price">K. N. Price</name><affiliation><nlm:aff id="mdv391_af12"><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></nlm:aff></affiliation></author><author><name sortKey="Gelber, R D" sort="Gelber, R D" uniqKey="Gelber R" first="R. D." last="Gelber">R. D. Gelber</name><affiliation><nlm:aff id="mdv391_af2"><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af13"><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Coates, A S" sort="Coates, A S" uniqKey="Coates A" first="A. S." last="Coates">A. S. Coates</name><affiliation><nlm:aff id="mdv391_af14"><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></nlm:aff></affiliation><affiliation><nlm:aff id="mdv391_af15"><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, A" sort="Goldhirsch, A" uniqKey="Goldhirsch A" first="A." last="Goldhirsch">A. Goldhirsch</name><affiliation><nlm:aff id="mdv391_af16"><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Colleoni, M" sort="Colleoni, M" uniqKey="Colleoni M" first="M." last="Colleoni">M. Colleoni</name><affiliation><nlm:aff id="mdv391_af1"><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></nlm:aff></affiliation></author></analytic><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Oncol</journal-id><journal-id journal-id-type="publisher-id">annonc</journal-id><journal-id journal-id-type="hwp">annonc</journal-id><journal-title-group><journal-title>Annals of Oncology</journal-title></journal-title-group><issn pub-type="ppub">0923-7534</issn><issn pub-type="epub">1569-8041</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26387144</article-id><article-id pub-id-type="pmc">4658543</article-id><article-id pub-id-type="doi">10.1093/annonc/mdv391</article-id><article-id pub-id-type="publisher-id">mdv391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Breast Tumors</subject></subj-group></subj-group></article-categories><title-group><article-title>Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Munzone</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="mdv391_af1">1</xref><xref ref-type="corresp" rid="mdv391_cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdv391_af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gusterson</surname><given-names>B. A.</given-names></name><xref ref-type="aff" rid="mdv391_af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mallon</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="mdv391_af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Viale</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thürlimann</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="mdv391_af6">6</xref><xref ref-type="aff" rid="mdv391_af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ejlertsen</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="mdv391_af8">8</xref></contrib><contrib contrib-type="author"><name><surname>MacGrogan</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Bibeau</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="mdv391_af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Lelkaitis</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="mdv391_af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>K. N.</given-names></name><xref ref-type="aff" rid="mdv391_af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>R. D.</given-names></name><xref ref-type="aff" rid="mdv391_af2">2</xref><xref ref-type="aff" rid="mdv391_af13">13</xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="mdv391_af14">14</xref><xref ref-type="aff" rid="mdv391_af15">15</xref></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="mdv391_af16">16</xref></contrib><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="mdv391_af1">1</xref></contrib><on-behalf-of>for the International Breast Cancer Study Group and the BIG 1-98 Collaborative Group</on-behalf-of><aff id="mdv391_af1"><label>1</label><addr-line>Division of Medical Senology</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff><aff id="mdv391_af2"><label>2</label><addr-line>Department of Biostatistics and Computational Biology</addr-line>,<institution>International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute</institution>,<addr-line>Boston</addr-line>,<country>USA</country></aff><aff id="mdv391_af3"><label>3</label><institution>Institute of Cancer Sciences, Glasgow University</institution>,<addr-line>Glasgow</addr-line></aff><aff id="mdv391_af4"><label>4</label><institution>Southern General Hospital</institution>,<addr-line>Glasgow</addr-line>,<country>UK</country></aff><aff id="mdv391_af5"><label>5</label><addr-line>Department of Pathology and Laboratory Medicine</addr-line>,<institution>IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff><aff id="mdv391_af6"><label>6</label><institution>Breast Center, Kantonsspital</institution>,<addr-line>St Gallen</addr-line></aff><aff id="mdv391_af7"><label>7</label><institution>Swiss Group for Clinical Cancer Research (SAKK)</institution>,<addr-line>Bern</addr-line>,<country>Switzerland</country></aff><aff id="mdv391_af8"><label>8</label><institution>Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></aff><aff id="mdv391_af9"><label>9</label><addr-line>Department of Pathology</addr-line>,<institution>Institut Bergonié</institution>,<addr-line>Bordeaux</addr-line></aff><aff id="mdv391_af10"><label>10</label><addr-line>Department of Pathology</addr-line>,<institution>Val d'Aurelle Cancer Institute</institution>,<addr-line>Montpellier</addr-line>,<country>France</country></aff><aff id="mdv391_af11"><label>11</label><addr-line>Department of Pathology</addr-line>,<institution>Rigshospitalet</institution>,<addr-line>Copenhagen</addr-line>,<country>Denmark</country></aff><aff id="mdv391_af12"><label>12</label><institution>International Breast Cancer Study Group (IBCSG) Statistical Center</institution></aff><aff id="mdv391_af13"><label>13</label><addr-line>Harvard T.H. Chan School of Public Health, Harvard Medical School</addr-line>,<institution>Frontier Science and Technology Research Foundation</institution>,<addr-line>Boston</addr-line>,<country>USA</country></aff><aff id="mdv391_af14"><label>14</label><addr-line>International Breast Cancer Study Group, Bern</addr-line>,<institution>Switzerland</institution></aff><aff id="mdv391_af15"><label>15</label><institution>University of Sydney</institution>,<addr-line>Sydney</addr-line>,<country>Australia</country></aff><aff id="mdv391_af16"><label>16</label><addr-line>Program of Breast Health</addr-line>,<institution>European Institute of Oncology</institution>,<addr-line>Milan</addr-line>,<country>Italy</country></aff></contrib-group><author-notes><corresp id="mdv391_cor1"><label>*</label><italic>Correspondence to:</italic> Dr Elisabetta Munzone, Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Tel: +39-02-57489502; E-mail: <email>elisabetta.munzone@ieo.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 12 months and
0 days and was based on the
<volume>26</volume><issue>12</issue><fpage>2442</fpage><lpage>2449</lpage><history><date date-type="received"><day>9</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>3</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:href="mdv391.pdf"></self-uri><abstract abstract-type="precis"><p>In the BIG 1-98 clinical trial of 4922 postmenopausal women treated with 5 years of letrozole or tamoxifen for endocrine-responsive breast cancer, 183 had the rare histotypes mucinous or tubular/cribriform. These women had better outcomes than those with other histotypes. The magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with these rare histotypes.</p></abstract><abstract><sec><title>Background</title><p>We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.</p></sec><sec><title>Patients and methods</title><p>The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy with tamoxifen or letrozole) included 4922 women, of whom 4091 had central pathology review. Histotype groups were defined as: mucinous (<italic>N</italic> = 100), tubular/cribriform (<italic>N</italic> = 83), ductal (<italic>N</italic> = 3257), and other (<italic>N</italic> = 651). Of 183 women with either mucinous or tubular/cribriform tumors, 96 were randomly assigned to letrozole and 87 to tamoxifen. Outcomes assessed were disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI). Median follow-up in the analytic cohort was 8.1 years.</p></sec><sec><title>Results</title><p>Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97.5% 5-year BCFI) than those with mucinous (93.5%), ductal (88.9%), or other (89.9%) histotypes. Patients with mucinous or tubular/cribriform carcinoma had better DRFI (5-year rates 97.8% and 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) carcinomas. Within the subgroup of women with special histotypes, we observed a nonsignificant increase in the hazard of breast cancer recurrence with letrozole [hazard (letrozole versus tamoxifen): 3.31, 95% confidence interval 0.94–11.7; <italic>P</italic> = 0.06].</p></sec><sec><title>Conclusions</title><p>Women with mucinous or tubular/cribriform breast cancer have better outcomes than those with other histotypes, although the observation is based on a limited number of events. In postmenopausal women with these histotypes, the magnitude of the letrozole advantage compared with tamoxifen may not be as large in patients with mucinous or tubular/cribriform disease.</p></sec><sec><title>Clinicaltrials.gov</title><p>NCT00004205.</p></sec></abstract><kwd-group><kwd>letrozole</kwd><kwd>tamoxifen</kwd><kwd>mucinous</kwd><kwd>tubular</kwd><kwd>cribriform</kwd><kwd>breast cancer</kwd></kwd-group><funding-group><award-group id="funding-1"><funding-source>Novartis <named-content content-type="funder-id">http://dx.doi.org/10.13039/100004336</named-content></funding-source></award-group><award-group id="funding-2"><funding-source>IBCSG: Swedish Cancer Society,</funding-source></award-group><award-group id="funding-3"><funding-source>US National Institute of Health</funding-source></award-group><award-group id="funding-4"><funding-source>Foundation for Clinical Cancer Research of Eastern Switzerland</funding-source></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |